

7. Literaturlisten

7.1 Literatur

1. Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A, Feuer EJ, Thun MJ. Cancer statistics, 2005. *CA Cancer J Clin* 2005;55:10-30.
2. Polascik TJ, Oesterling JE, Partin AW. Prostate specific antigen: a decade of discovery-what we have learned and where we are going. *J Urol* 1999;162:293-306.
3. Wang MC, Valenzuela LA, Murphy GP, Chu TM. Purification of a human prostate specific antigen. *Invest Urol* 1979;17:159-63.
4. Papsidero LD, Wang MC, Valenzuela LA, Murphy GP, Chu TM. A prostate antigen in sera of prostatic cancer patients. *Cancer Res* 1980;40:2428-32.
5. Wang MC, Papsidero LD, Kuriyama M, Valenzuela LA, Murphy GP, Chu TM. Prostate antigen: a new potential marker for prostatic cancer. *Prostate* 1981;2:89-96.
6. Catalona WJ, Smith DS, Ratliff TL, Dodds KM, Coplen DE, Yuan JJ, Petros JA, Andriole GL. Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. *N Engl J Med* 1991;324:1156-61.
7. Stamey TA, Yang N, Hay AR, McNeal JE, Freiha FS, Redwine E. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. *N Engl J Med* 1987;317:909-16.
8. Ward AM, Catto JW, Hamdy FC. Prostate specific antigen: biology, biochemistry and available commercial assays. *Ann Clin Biochem* 2001;38:633-51.
9. Brawer MK, Chetner MP, Beatie J, Buchner DM, Vessella RL, Lange PH. Screening for prostatic carcinoma with prostate specific antigen. *J Urol* 1992;147:841-5.
10. Catalona WJ, Smith DS, Ratliff TL, Basler JW. Detection of organ-confined prostate cancer is increased through prostate-specific antigen-based screening. *JAMA* 1993;270:948-54.
11. Cooner WH, Mosley BR, Rutherford CL, Jr., Beard JH, Pond HS, Terry WJ, Igel TC, Kidd DD. Prostate cancer detection in a clinical urological practice by ultrasonography, digital rectal examination and prostate specific antigen. *J Urol* 1990;143:1146-52.
12. Brawer MK. Screening for prostate cancer. *Semin Surg Oncol* 2000;18:29-36.
13. Horninger W, Reissigl A, Rogatsch H, Volgger H, Studen M, Klocker H, Bartsch G. Prostate cancer screening in the Tyrol, Austria: experience and results. *Eur J Cancer* 2000;36:1322-35.
14. Catalona WJ, Richie JP, Ahmann FR, Hudson MA, Scardino PT, Flanigan RC, deKernion JB, Ratliff TL, Kavoussi LR, Dalkin BL. Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6,630 men. *J Urol* 1994;151:1283-90.
15. Bunting PS. A guide to the interpretation of serum prostate specific antigen levels. *Clin Biochem* 1995;28:221-41.
16. Diamandis EP, Yu H. Nonprostatic sources of prostate-specific antigen. *Urol Clin North Am* 1997;24:275-82.
17. Thompson IM, Pauler DK, Goodman PJ, Tangen CM, Lucia MS, Parnes HL, Minasian LM, Ford LG, Lippman SM, Crawford ED, Crowley JJ, Coltman CA, Jr. Prevalence of prostate cancer among men with a prostate-specific antigen level \leq 4.0 ng per milliliter. *N Engl J Med* 2004;350:2239-46.
18. Benson MC, Whang IS, Pantuck A, Ring K, Kaplan SA, Olsson CA, Cooner WH. Prostate specific antigen density: a means of distinguishing benign prostatic hypertrophy and prostate cancer. *J Urol* 1992;147:815-6.
19. Carter HB, Pearson JD. PSA velocity for the diagnosis of early prostate cancer. A new concept. *Urol Clin North Am* 1993;20:665-70.
20. Oesterling JE, Jacobsen SJ, Chute CG. Serum prostate-specific antigen in a community-based population of healthy men: establishment of age-specific reference ranges. *JAMA* 1993;270:860-6.
21. Catalona WJ, Southwick PC, Slawin KM, Partin AW, Brawer MK, Flanigan RC, Patel A, Richie JP, Walsh PC, Scardino PT, Lange PH, Gasior GH, Loveland KG, Bray KR. Comparison of percent free PSA, PSA density, and age-specific PSA cutoffs for prostate cancer detection and staging. *Urology* 2000;56:255-60.
22. Ciatto S, Bonardi R, Lombardi C, Zappa M, Gervasi G, Cappelli G. Analysis of PSA velocity in 1666 healthy subjects undergoing total PSA determination at two consecutive screening rounds. *Int J Biol Markers* 2002;17:79-83.
23. Nixon RG, Brawer MK. Enhancing the specificity of prostate-specific antigen (PSA): an overview of PSA density, velocity and age-specific reference ranges. *Br J Urol* 1997;79 Suppl 1:61-7.
24. Christensson A, Björk T, Nilsson O, Dahlen U, Matikainen MT, Cockett AT, Abrahamsson PA, Lilja H. Serum prostate specific antigen complexed to alpha 1-antichymotrypsin as an indicator of prostate cancer. *J Urol* 1993;150:100-5.
25. Lilja H, Christensson A, Dahlen U, Matikainen MT, Nilsson O, Pettersson K, Lövgren T. Prostate-specific antigen in serum occurs predominantly in complex with alpha 1-antichymotrypsin. *Clin Chem* 1991;37:1618-25.

26. Stenman UH, Leinonen J, Alfthan H, Rannikko S, Tuhkanen K, Alfthan O. A complex between prostate-specific antigen and alpha 1-antichymotrypsin is the major form of prostate-specific antigen in serum of patients with prostatic cancer: assay of the complex improves clinical sensitivity for cancer. *Cancer Res* 1991;51:222-6.
27. Lein M, **Stephan C**, Jung K, Schnorr D, Loening SA. [Molecular forms of prostate-specific antigen and human kallikrein 2 as possible indicators in prostatic carcinoma diagnosis]. *Urologe A* 2000;39:313-23.
28. Wu JT, Zhang P, Liu GH, Wilson L. Development of an immunoassay specific for the PSA-ACT complex without the problem of high background. *J Clin Lab Anal* 1998;12:14-9.
29. **Stephan C**, Jung K, Lein M, Sinha P, Schnorr D, Loening SA. Molecular forms of prostate-specific antigen and human kallikrein 2 as promising tools for early diagnosis of prostate cancer. *Cancer Epidemiol Biomarkers Prev* 2000;9:1133-47.
30. Allard WJ, Zhou Z, Yeung KK. Novel immunoassay for the measurement of complexed prostate-specific antigen in serum. *Clin Chem* 1998;44:1216-23.
31. Zhang WM, Leinonen J, Kalkkinen N, Stenman U-H. Prostate-specific antigen forms a complex with and cleaves a₁-protease inhibitor in vitro. *Prostate* 1997;33:87-96.
32. Christensson A, Lilja H. Complex formation between protein C inhibitor and prostate-specific antigen in vitro and in human semen. *Eur J Biochem* 1994;220:45-53.
33. Christensson A, Laurell CB, Lilja H. Enzymatic activity of prostate-specific antigen and its reactions with extracellular serine proteinase inhibitors. *Eur J Biochem* 1990;194:755-63.
34. Zhang WM, Finne P, Leinonen J, Vesalainen S, Nordling S, Rannikko S, Stenman UH. Characterization and immunological determination of the complex between prostate-specific antigen and alpha2-macroglobulin. *Clin Chem* 1998;44:2471-9.
35. Zhang WM, Finne P, Leinonen J, Salo J, Stenman UH. Determination of prostate-specific antigen complexed to alpha(2)-macroglobulin in serum increases the specificity of free to total PSA for prostate cancer. *Urology* 2000;56:267-72.
36. Zhang WM, Finne P, Leinonen J, Vesalainen S, Nordling S, Stenman UH. Measurement of the complex between prostate-specific antigen and alpha1-protease inhibitor in serum. *Clin Chem* 1999;45:814-21.
37. Bangma CH, Rietbergen JB, Kranse R, Blijenberg BG, Petterson K, Schroder FH. The free-to-total prostate specific antigen ratio improves the specificity of prostate specific antigen in screening for prostate cancer in the general population. *J Urol* 1997;157:2191-6.
38. Catalona WJ, Smith DS, Ornstein DK. Prostate cancer detection in men with serum PSA concentrations of 2.6 to 4.0 ng/mL and benign prostate examination. Enhancement of specificity with free PSA measurements. *JAMA* 1997;277:1452-5.
39. Catalona WJ, Partin AW, Slawin KM, Brawer MK, Flanigan RC, Patel A, Richie JP, deKernion JB, Walsh PC, Scardino PT, Lange PH, Subong EN, Parson RE, Gasior GH, Loveland KG, Southwick PC. Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial. *JAMA* 1998;279:1542-7.
40. Jung K, **Stephan C**, Lein M, Henke W, Schnorr D, Brux B, Schürenkämper P, Loening SA. Analytical performance and clinical validity of two free prostate-specific antigen assays compared. *Clin Chem* 1996;42:1026-33.
41. Partin AW, Catalona WJ, Southwick PC, Subong EN, Gasior GH, Chan DW. Analysis of percent free prostate-specific antigen (PSA) for prostate cancer detection: influence of total PSA, prostate volume, and age. *Urology* 1996;48:55-61.
42. Van Cangh PJ, De Nayer P, De Vischer L, Sauvage P, Tombal B, Lorge F, Wese FX, Opsomer R. Free to total prostate-specific antigen (PSA) ratio improves the discrimination between prostate cancer and benign prostatic hyperplasia (BPH) in the diagnostic gray zone of 1.8 to 10 ng/mL total PSA. *Urology* 1996;48:67-70.
43. Catalona WJ. Clinical utility of measurements of free and total prostate-specific antigen (PSA): a review. *Prostate Suppl* 1996;7:64-9.
44. Woodrum DL, Brawer MK, Partin AW, Catalona WJ, Southwick PC. Interpretation of free prostate specific antigen clinical research studies for the detection of prostate cancer. *J Urol* 1998;159:5-12.
45. Catalona WJ, Partin AW, Finlay JA, Chan DW, Rittenhouse HG, Wolfert RL, Woodrum DL. Use of percentage of free prostate-specific antigen to identify men at high risk of prostate cancer when PSA levels are 2.51 to 4 ng/mL and digital rectal examination is not suspicious for prostate cancer: an alternative model. *Urology* 1999;54:220-4.
46. Jung K, **Stephan C**, Elgeti U, Lein M, Brux B, Kristiansen G, Rudolph B, Hauptmann S, Schnorr D, Loening SA. Molecular forms of prostate-specific antigen in serum with concentrations of total prostate-specific antigen <4 µg/l - are they useful tools for early detection and screening of prostate cancer? *Int J Cancer* 2001;93:759-65.
47. Roehl KA, Antenor JA, Catalona WJ. Robustness of free prostate specific antigen measurements to reduce unnecessary biopsies in the 2.6 to 4.0 ng./ml. range. *J Urol* 2002;168:922-5.
48. Catalona WJ, Smith DS, Wolfert RL, Wang TJ, Rittenhouse HG, Ratliff TL, Nadler RB. Evaluation of percentage of free serum prostate-specific antigen to improve specificity of prostate cancer screening. *JAMA* 1995;274:1214-20.

49. **Stephan C**, Jung K, Diamandis EP, Rittenhouse HG, Lein M, Loening SA. Prostate specific antigen, its molecular forms, and other kallikrein markers for detection of prostate cancer. *Urology* 2002;59:2-8.
50. **Stephan C**, Jung K, Sinha P. Tumor markers for prostatic cancer - which way in this millenium? *Res Adv in Cancer* 2002;2:147-57.
51. Stenman UH, Leinonen J, Zhang WM, Finne P. Prostate-specific antigen. *Semin Cancer Biol* 1999;9:83-93.
52. Mikolajczyk SD, Marks LS, Partin AW, Rittenhouse HG. Free prostate-specific antigen in serum is becoming more complex. *Urology* 2002;59:797-802.
53. **Stephan C**, Jung K, Lein M, Henke W, Schnorr D, Brux B, Loening S. Freies prostataspezifisches Antigen im Serum: eine Meßgröße zur Diskrimination zwischen Patienten mit Prostatakarzinom und benigner Prostatahyperplasie. *J Lab Med* 1996;20:7-12.
54. Lein M, Jung K, **Stephan C**, Lenk S, Schnorr D, Loening SA. PSA-Quotient ist spezifischer als Absolutwerte. *TW Urologie Nephrologie* 1997;9:235-7.
55. Lein M, **Stephan C**, Jung K, Koenig F, Schnorr D, Loening SA. Das Verhältnis freies PSA/Gesamt-PSA - eine Kenngröße zur Differenzierung zwischen Patienten mit Prostatakarzinom und benigner Hyperplasie: Welcher Diskriminationspunkt sollte gewählt werden? *Akt Urol* 1997;28:323-8.
56. Jung K, v.Klinggräff P, Brux B, Sinha P, Schnorr D, Loening SA. Preanalytical determinants of total and free prostate-specific antigen and their ratio: blood collection and storage conditions. *Clin Chem* 1998;44:685-8.
57. Jung K, Lein M, Brux B, Sinha P, Schnorr D, Loening SA. Different stability of free and complexed prostate-specific antigen in serum in relation to specimen handling and storage conditions. *Clin Chem Lab Med* 2000;38:1271-5.
58. **Stephan C**, Jung K, Lein M, Schnorr D, Loening SA. The ratio of free to total prostate specific antigen in serum is correlated to the prostate volume. *Int J Cancer* 1996;67:461-2.
59. **Stephan C**, Lein M, Jung K, Schnorr D, Loening SA. The influence of prostate volume on the ratio of free to total prostate specific antigen in serum of patients with prostate carcinoma and benign prostate hyperplasia. *Cancer* 1997;79:104-9.
60. Haese A, Graefen M, Noldus J, Hammerer P, Huland E, Huland H. Prostatic volume and ratio of free-to-total prostate specific antigen in patients with prostatic cancer or benign prostatic hyperplasia. *J Urol* 1997;158:2188-92.
61. **Stephan C**, Lein M, Jung K, Schnorr D, Loening SA. Can prostate specific antigen derivatives reduce the frequency of unnecessary prostate biopsies?[Letter]. *J Urol* 1997;157:1371.
62. Lein M, **Stephan C**, Jung K, Schnorr D, Loening S. Relation of free PSA/total PSA in serum for differentiating between patients with prostatic cancer and benign hyperplasia of the prostate: which cutoff should be used? *Cancer Invest* 1998;16:45-9.
63. **Stephan C**, Stroebel G, Heinau M, Lenz A, Roemer A, Lein M, Schnorr D, Loening SA, Jung K. The ratio of prostate-specific antigen (PSA) to prostate volume (PSA density) as a parameter to improve the detection of prostate carcinoma in PSA values in the range of < 4 ng/mL. *Cancer* 2005;104:993-1003.
64. Lein M, Koenig F, Jung K, McGovern FJ, Skates SJ, Schnorr D, Loening SA. The percentage of free prostate specific antigen is an age-independent tumour marker for prostate cancer: establishment of reference ranges in a large population of healthy men. *Br J Urol* 1998;82:231-6.
65. Lein M, Brux B, Jung K, Henke W, Koenig F, **Stephan C**, Schnorr D, Loening SA. Elimination of serum free and total prostate-specific antigen after radical retropubic prostatectomy. *Eur J Clin Chem Clin Biochem* 1997;35:591-5.
66. **Stephan C**, Jung K, Brux B, Sinha P, Lein M, Schnorr D, Loening SA. Elimination of serum complexed prostate-specific antigen after radical retropubic prostatectomy. *Clin Chem Lab Med* 2000;38:309-11.
67. **Stephan C**, Jung K, Brux B, Lein M, Sinha P, Schnorr D, Loening SA. ACT-PSA and complexed PSA elimination kinetics in serum after radical retropubic prostatectomy: proof of new complex forming of PSA after release into circulation. *Urology* 2000;55:560-3.
68. Lein M, Jung K, Elgeti U, Petras T, **Stephan C**, Brux B, Sinha P, Winkelmann B, Schnorr D, Loening S. Comparison of the clinical validity of free prostate-specific antigen, alpha-1 antichymotrypsin-bound prostate-specific antigen and complexed prostate-specific antigen in prostate cancer diagnosis. *Eur Urol* 2001;39:57-64.
69. Lein M, Jung K, Hammerer P, Graefen M, Semjonow A, Stieber P, Ossendorf M, Brux B, **Stephan C**, Schnorr D, Loening SA. A multicenter clinical trial on the use of alpha₁-antichymotrypsin-prostate-specific antigen in prostate cancer diagnosis. *Prostate* 2001;47:77-84.
70. Lein M, Kwiatkowski M, Semjonow A, Luboldt HJ, Hammerer P, **Stephan C**, Klevecka V, Taymoorian K, Schnorr D, Recker F, Loening SA, Jung K. A multicenter clinical trial on the use of complexed prostate specific antigen in low prostate specific antigen concentrations. *J Urol* 2003;170:1175-9.
71. **Stephan C**, Schnorr D, Loening SA, Jung K. Re: Roddam AW, Duffy MJ, Hamdy FC, et al. Use of prostate-specific antigen (PSA) isoforms for the detection of prostate cancer in men with a PSA level of 2-10 ng/ml: systematic review and meta-analysis. *Eur Urol* 2005;48:386-99. *Eur Urol* 2005;48:1059-60.
72. **Stephan C**, Jung K, Schnorr D, Lein M, Sinha P, Loening SA. Re: A prospective study to evaluate the role of complexed prostate specific antigen and free/total prostate specific antigen ratio for the diagnosis of

- prostate cancer. I.D.C. Mitchell, B.L. Croal, A. Dickie, N.P. Cohen and I. Ross. *J Urol*, 165: 1549-1553, 2001. *J Urol* 2002;167:259-60.
73. **Stephan C**, Jung K, Lein M, Schnorr D, Loening SA. Re: Complexed prostate specific antigen provides significant enhancement of specificity compared with total prostate specific antigen for detecting prostate cancer. *J Urol* 2000;164:1671-2.
 74. **Stephan C**, Jung K. Indirect free PSA and other molecular forms of PSA: Are there new tools for prostate cancer detection? *LabMedica Int* 2004;21:15-9.
 75. Wesseling S, **Stephan C**, Semjonow A, Lein M, Brux B, Sinha P, Loening SA, Jung K. Determination of non-alpha1-antichymotrypsin-complexed prostate-specific antigen as an indirect measurement of free prostate-specific antigen: analytical performance and diagnostic accuracy. *Clin Chem* 2003;49:887-94.
 76. Jung K, Reiche J, Boehme A, **Stephan C**, Loening SA, Schnorr D, Hoesel W, Sinha P. Analysis of subforms of free prostate-specific antigen in serum by two-dimensional gel electrophoresis: potential to improve diagnosis of prostate cancer. *Clin Chem* 2004;50:2292-301.
 77. Jung K, **Stephan C**, Lein M, Brux B, Sinha P, Schnorr D, Loening SA. Receiver-operating characteristic as a tool for evaluating the diagnostic performance of prostate-specific antigen and its molecular forms-What has to be considered? *Prostate* 2001;46:307-10.
 78. **Stephan C**, Wesseling S, Schink T, Jung K. Comparison of eight computer programs for receiver-operating characteristic (ROC) analysis. *Clin Chem* 2003;49:433-9.
 79. Keller T, Butz H, Lein M, Kwiatkowski M, Semjonow A, Luboldt HJ, Hammerer P, **Stephan C**, Jung K. Discordance analysis characteristics as a new method to compare the diagnostic accuracy of tests: example of complexed versus total prostate-specific antigen. *Clin Chem* 2005;51:532-9.
 80. Jung K, Lein M, Butz H, **Stephan C**, Loening SA, Keller T. New insights into the diagnostic accuracy of complexed and total prostate specific antigen using discordance analysis characteristics. *J Urol* 2006;in press.
 81. **Stephan C**, Cammann H, Jung K. Viewpoint: Artificial neural networks: has the time come for their use in prostate cancer patients? *Nature Clin Pract Urol* 2005;2:262-3.
 82. Dreiseitl S, Ohno-Machado L. Logistic regression and artificial neural network classification models: a methodology review. *J Biomed Inform* 2002;35:352-9.
 83. Snow PB, Smith DS, Catalona WJ. Artificial neural networks in the diagnosis and prognosis of prostate cancer: a pilot study. *J Urol* 1994;152:1923-6.
 84. Carlson GD, Calvanese CB, Partin AW. An algorithm combining age, total prostate-specific antigen (PSA), and percent free PSA to predict prostate cancer: results on 4298 cases. *Urology* 1998;52:455-61.
 85. Finne P, Finne R, Auvinen A, Juusela H, Aro J, Maattanen L, Hakama M, Rannikko S, Tammela TL, Stenman U. Predicting the outcome of prostate biopsy in screen-positive men by a multilayer perceptron network. *Urology* 2000;56:418-22.
 86. Babaian RJ, Fritsche H, Ayala A, Bhadkamkar V, Johnston DA, Naccarato W, Zhang Z. Performance of a neural network in detecting prostate cancer in the prostate-specific antigen reflex range of 2.5 to 4.0 ng/mL. *Urology* 2000;56:1000-6.
 87. Djavan B, Remzi M, Zlotta A, Seitz C, Snow P, Marberger M. Novel artificial neural network for early detection of prostate cancer. *J Clin Oncol* 2002;20:921-9.
 88. Garzotto M, Hudson RG, Peters L, Hsieh YC, Barrera E, Mori M, Beer TM, Klein T. Predictive modeling for the presence of prostate carcinoma using clinical, laboratory, and ultrasound parameters in patients with prostate specific antigen levels $< \text{or} = 10 \text{ ng/mL}$. *Cancer* 2003;98:1417-22.
 89. Kalra P, Togami J, Bansal BSG, Partin AW, Brawer MK, Babaian RJ, Ross LS, Niederberger CS. A neurocomputational model for prostate carcinoma detection. *Cancer* 2003;98:1849-54.
 90. Remzi M, Anagnostou T, Ravery V, Zlotta A, **Stephan C**, Marberger M, Djavan B. An artificial neural network to predict the outcome of repeat prostate biopsies. *Urology* 2003;62:456-60.
 91. **Stephan C**, Jung K, Cammann H, Vogel B, Brux B, Kristiansen G, Rudolph B, Hauptmann S, Lein M, Schnorr D, Sinha P, Loening SA. An artificial neural network considerably improves the diagnostic power of percent free prostate-specific antigen in prostate cancer diagnosis: Results of a 5-year investigation. *Int J Cancer* 2002;99:466-73.
 92. Costa A, Gennari R, Andreoli C, Betka J, **Stephan C**, Hugosson J, Llovet JM, Melia J, Nakhosteen JA, Quaranta M, Rosselli del Turco M, Schittulli F, Sideri M, Zurrada S, Veronesi U. Individual risk assessment and early detection of cancer. *Eur J Cancer* 2005;submitted.
 93. **Stephan C**, Yousef GM, Jung K, Diamandis EP. Prostate specific antigen and other kallikreins in prostate cancer. In: Paschalides P, ed. *Prostate Cancer: Understanding the Pathophysiology and Redesigning a Therapeutic Approach*. 2005;in press.
 94. **Stephan C**, Cammann H, Jung K, Loening SA. Multivariate models for decreasing unnecessary biopsies for prostate cancer. In: Kirby R, Partin AW, Feneley M, Kellogg Parsons J, eds. *Prostate Cancer: Principles and Practice*. 2005.
 95. **Stephan C**, Cammann H, Semjonow A, Diamandis EP, Wymenga LFA, Lein M, Sinha P, Loening SA, Jung K. Multicenter evaluation of an artificial neural network to increase prostate cancer detection rate and reduce unnecessary biopsies. *Clin Chem* 2002;48:1279-87.

96. **Stephan C**, Vogel B, Cammann H, Lein M, Klevecka V, Sinha P, Kristiansen G, Schnorr D, Jung K, Loening SA. Nutzung von artifiziellen neuronalen Netzwerken zur Risikoabschätzung eines Prostatakarzinoms: Biopsieindikationen im PSA-Bereich 2-20 µg/l. *Urologe A* 2003;42:1221-9.
97. **Stephan C**, Lein M, Schnorr D, Loening SA, Jung K. Repeating the measurement of prostate-specific antigen in symptomatic men can avoid unnecessary prostatic biopsy. *BJU Int* 2004;93:1360-1.
98. Semjonow A, Oberpenning F, Brandt B, Zechel C, Brandau W, Hertle L. Impact of free prostate-specific antigen on discordant measurement results of assays for total prostate-specific antigen. *Urology* 1996;48 (Suppl):10-5.
99. **Stephan C**, Xu C, Cammann H, Graefen M, Haese A, Huland H, Semjonow A, Diamandis EP, Remzi M, Djavan B, Wildhagen MF, Blijenberg BG, Finne P, Stenman UH, Meyer H, Jung K. Assay-specific artificial neural networks for 5 different PSA assays and populations with PSA 2-10 ng/mL in 4480 men. *Cancer* 2005;submitted.
100. **Stephan C**, Klaas M, Müller C, Schnorr D, Loening SA, Jung K. Interchangeability of measurements of total and free prostate-specific antigen in serum with 5 frequently used assay combinations: an update. *Clin Chem* 2006;in press.
101. Catalona WJ, Bartsch G, Rittenhouse HG, Evans CL, Linton HJ, Amirkhan A, Horninger W, Klocker H, Mikolajczyk SD. Serum pro prostate specific antigen improves cancer detection compared to free and complexed prostate specific antigen in men with prostate specific antigen 2 to 4 ng/ml. *J Urol* 2003;170:2181-5.
102. Catalona WJ, Bartsch G, Rittenhouse HG, Evans CL, Linton HJ, Horninger W, Klocker H, Mikolajczyk SD. Serum pro-prostate specific antigen preferentially detects aggressive prostate cancers in men with 2 to 4 ng/ml prostate specific antigen. *J Urol* 2004;171:2239-44.
103. Mikolajczyk SD, Millar LS, Wang TJ, Rittenhouse HG, Marks LS, Song W, Wheeler TM, Slawin KM. A precursor form of prostate-specific antigen is more highly elevated in prostate cancer compared with benign transition zone prostate tissue. *Cancer Res* 2000;60:756-9.
104. Mikolajczyk SD, Catalona WJ, Evans CL, Linton HJ, Millar LS, Marker KM, Katir D, Amirkhan A, Rittenhouse HG. Proenzyme forms of prostate-specific antigen in serum improve the detection of prostate cancer. *Clin Chem* 2004;50:1017-25.
105. Peter J, Unverzagt C, Krogh TN, Vorm O, Hoesel W. Identification of precursor forms of free prostate-specific antigen in serum of prostate cancer patients by immunosorption and mass spectrometry. *Cancer Res* 2001;61:957-62.
106. Lein M, Semjonow A, Graefen M, Kwiatkowski M, Abramjuk C, **Stephan C**, Haese A, Chun F, Schnorr D, Loening SA, Jung K. A multicenter clinical trial on the use of (-5, -7) pro prostate specific antigen. *J Urol* 2005;174:2150-3.
107. Bangma CH, Wildhagen MF, Yurdakul G, Schroder FH, Blijenberg BG. The value of (-7, -5)pro-prostate-specific antigen and human kallikrein-2 as serum markers for grading prostate cancer. *BJU Int* 2004;93:720-4.
108. **Stephan C**, Meyer H, Kwiatkowski M, Recker F, Cammann H, Loening SA, Jung K, Lein M. A (-5, -7) Pro PSA based artificial neuronal network to detect prostate cancer. *Eur Urol* 2005;submitted.
109. Diamandis EP, Yousef GM, Clements J, Ashworth LK, Yoshida S, Egelrud T, Nelson PS, Shiosaka S, Little S, Lilja H, Stenman UH, Rittenhouse HG, Wain H. New nomenclature for the human tissue kallikrein gene family. *Clin Chem* 2000;46:1855-8.
110. Diamandis EP, Okui A, Mitsui S, Luo LY, Soosaipillai A, Grass L, Nakamura T, Howarth DJ, Yamaguchi N. Human kallikrein 11: A new biomarker of prostate and ovarian carcinoma. *Cancer Res* 2002;62:295-300.
111. Nakamura T, Scorilas A, **Stephan C**, Jung K, Soosaipillai AR, Diamandis EP. The usefulness of serum human kallikrein 11 for discriminating between prostate cancer and benign prostatic hyperplasia. *Cancer Res* 2003;63:6543-6.
112. Brown DA, **Stephan C**, Ward RL, Law M, Hunter M, Bauskin AR, Amin J, Jung K, Diamandis EP, Hampton GM, Russell PJ, Giles GG, Breit SN. Serum macrophage inhibitory cytokine-1 (MIC-1) levels for the diagnosis and tumor grading of prostate cancer. *Clin Cancer Res* 2005;accepted.
113. Bootcov MR, Bauskin AR, Valenzuela SM, Moore AG, Bansal M, He XY, Zhang HP, Donnellan M, Mahler S, Pryor K, Walsh BJ, Nicholson RC, Fairlie WD, Por SB, Robbins JM, Breit SN. MIC-1, a novel macrophage inhibitory cytokine, is a divergent member of the TGF-beta superfamily. *Proc Natl Acad Sci U S A* 1997;94:11514-9.
114. Brown DA, Breit SN, Buring J, Fairlie WD, Bauskin AR, Liu T, Ridker PM. Concentration in plasma of macrophage inhibitory cytokine-1 and risk of cardiovascular events in women: a nested case-control study. *Lancet* 2002;359:2159-63.
115. Moore AG, Brown DA, Fairlie WD, Bauskin AR, Brown PK, Munier ML, Russell PK, Salamonsen LA, Wallace EM, Breit SN. The transforming growth factor-ss superfamily cytokine macrophage inhibitory cytokine-1 is present in high concentrations in the serum of pregnant women. *J Clin Endocrinol Metab* 2000;85:4781-8.
116. Mitchell RA, Bucala R. Tumor growth-promoting properties of macrophage migration inhibitory factor (MIF). *Semin Cancer Biol* 2000;10:359-66.

117. Meyer-Siegler K, Fattor RA, Hudson PB. Expression of macrophage migration inhibitory factor in the human prostate. *Diagn Mol Pathol* 1998;7:44-50.
118. Meyer-Siegler KL, Bellino MA, Tannenbaum M. Macrophage migration inhibitory factor evaluation compared with prostate specific antigen as a biomarker in patients with prostate carcinoma. *Cancer* 2002;94:1449-56.
119. Michael A, **Stephan C**, Schnorr D, Loening SA, Jung K. Serum macrophage migration inhibitory factor is not elevated in patients with prostate cancer. *Cancer Epidemiol Biomarkers Prev* 2004;13:328-9.
120. Michael A, **Stephan C**, Kristiansen G, Burckhardt M, Loening SA, Schnorr D, Jung K. Diagnostic validity of macrophage migration inhibitory factor in serum of patients with prostate cancer: a re-evaluation. *Prostate* 2005;62:34-9.
121. **Stephan C**, Xu C, Brown DA, Breit SN, Michael A, Nakamura T, Diamandis EP, Cammann H, Jung K. Three new serum markers for prostate cancer detection within a percent free PSA based artificial neural network. *Prostate* 2006;in press.
122. Magklara A, Scorilas A, **Stephan C**, Kristiansen GO, Hauptmann S, Jung K, Diamandis EP. Decreased concentrations of prostate-specific antigen and human glandular kallikrein 2 in malignant versus nonmalignant prostatic tissue. *Urology* 2000;56:527-32.
123. **Stephan C**, Jung K, Soosaipillai A, Yousef GM, Cammann H, Meyer H, Xu C, Diamandis EP. Clinical utility of human glandular kallikrein 2 within a neural network for prostate cancer detection. *BJU Int* 2005;96:521-7.
124. **Stephan C**, Jung K, Nakamura T, Yousef GM, Kristiansen G, Diamandis EP. Serum human glandular kallikrein 2 (hK2) for distinguishing stage and grade of prostate cancer. *Int J Urol* 2005;accepted.
125. Magklara A, Scorilas A, Catalona WJ, Diamandis EP. The combination of human glandular kallikrein and free prostate-specific antigen (PSA) enhances discrimination between prostate cancer and benign prostatic hyperplasia in patients with moderately increased total PSA. *Clin Chem* 1999;45:1960-6.
126. Nam RK, Diamandis EP, Toi A, Trachtenberg J, Magklara A, Scorilas A, Papnastasiou PA, Jewett MA, Narod SA. Serum human glandular kallikrein-2 protease levels predict the presence of prostate cancer among men with elevated prostate-specific antigen. *J Clin Oncol* 2000;18:1036-42.
127. Partin AW, Catalona WJ, Finlay JA, Darte C, Tindall DJ, Young CY, Klee GG, Chan DW, Rittenhouse HG, Wolfert RL, Woodrum DL. Use of human glandular kallikrein 2 for the detection of prostate cancer: preliminary analysis. *Urology* 1999;54:839-45.
128. Recker F, Kwiatkowski MK, Piironen T, Pettersson K, Huber A, Lümnen G, Tscholl R. Human glandular kallikrein as a tool to improve discrimination of poorly differentiated and non-organ-confined prostate cancer compared with prostate-specific antigen. *Urology* 2000;55:481-5.
129. Haese A, Graefen M, Steuber T, Becker C, Pettersson K, Piironen T, Noldus J, Huland H, Lilja H. Human glandular kallikrein 2 levels in serum for discrimination of pathologically organ-confined from locally-advanced prostate cancer in total PSA-levels below 10 ng/ml. *Prostate* 2001;49:101-9.
130. Haese A, Graefen M, Becker C, Noldus J, Katz J, Cagiannos I, Kattan M, Scardino PT, Huland E, Huland H, Lilja H. The role of human glandular kallikrein 2 for prediction of pathologically organ confined prostate cancer. *Prostate* 2003;54:181-6.
131. Steuber T, Vickers AJ, Haese A, Becker C, Pettersson K, Chun FK, Kattan MW, Eastham JA, Scardino PT, Huland H, Lilja H. Risk assessment for biochemical recurrence prior to radical prostatectomy: Significant enhancement contributed by human glandular kallikrein 2 (hK2) and free prostate specific antigen (PSA) in men with moderate PSA-elevation in serum. *Int J Cancer* 2005.
132. Darson MF, Pacelli A, Roche P, Rittenhouse HG, Wolfert RL, Young CY, Klee GG, Tindall DJ, Bostwick DG. Human glandular kallikrein 2 (hK2) expression in prostatic intraepithelial neoplasia and adenocarcinoma: a novel prostate cancer marker. *Urology* 1997;49:857-62.
133. Darson MF, Pacelli A, Roche P, Rittenhouse HG, Wolfert RL, Saedi MS, Young CY, Klee GG, Tindall DJ, Bostwick DG. Human glandular kallikrein 2 expression in prostate adenocarcinoma and lymph node metastases. *Urology* 1999;53:939-44.
134. Sullivan PM, Etzioni R, Feng Z, Potter JD, Thompson ML, Thornquist M, Winget M, Yasui Y. Phases of biomarker development for early detection of cancer. *J Natl Cancer Inst* 2001;93:1054-61.
135. Yousef GM, Magklara A, Chang A, Jung K, Katsaros D, Diamandis EP. Cloning of a new member of the human kallikrein gene family, klk14, which is down-regulated in different malignancies. *Cancer Res* 2001;61:3425-31.
136. Yousef GM, Scorilas A, Jung K, Ashworth LK, Diamandis EP. Molecular cloning of the human kallikrein 15 gene (KLK15). Up-regulation in prostate cancer. *J Biol Chem* 2001;276:53-61.
137. Wittwer CT, Ririe KM, Andrew RV, David DA, Gundry RA, Balis UJ. The LightCycler: a microvolume multisample fluorimeter with rapid temperature control. *Biotechniques* 1997;22:176-81.
138. **Stephan C**, Yousef GM, Scorilas A, Jung K, Jung M, Kristiansen G, Hauptmann S, Bharaj BS, Nakamura T, Loening SA, Diamandis EP. Quantitative analysis of kallikrein 15 (KLK15) gene expression in prostate tissue. *J Urol* 2003;169:361-4.
139. Michael IP, Kurlender L, Memari N, Yousef GM, Du D, Grass L, **Stephan C**, Jung K, Diamandis EP. Intron retention: a common splicing event within the human kallikrein gene family. *Clin Chem* 2005;51:506-15.

140. Kurlender L, Yousef GM, Memari N, Robb JD, Michael IP, Borgono C, Katsaros D, **Stephan C**, Jung K, Diamandis EP. Differential expression of a human kallikrein 5 (KLK5) splice variant in ovarian and prostate cancer. *Tumour Biol* 2004;25:149-56.
141. Yousef GM, White NM, Kurlender L, Michael I, Memari N, Robb JD, Katsaros D, **Stephan C**, Jung K, Diamandis EP. The kallikrein gene 5 splice variant 2 is a new biomarker for breast and ovarian cancer. *Tumour Biol* 2004;25:221-7.
142. Shaw JLV, Grass L, Diamandis EP. Production of recombinant human kallikrein 15 protein and antibodies for development of an hk15 specific immunoassay. 1st International Symposium on kallikreins, Lausanne, September 1-3, 2005.
143. Yousef GM, **Stephan C**, Scorilas A, Ellatif MA, Jung K, Kristiansen G, Jung M, Polymeris ME, Diamandis EP. Differential expression of the human kallikrein gene 14 (KLK14) in normal and cancerous prostatic tissues. *Prostate* 2003;56:287-92.
144. Dhanasekaran SM, Barrette TR, Ghosh D, Shah R, Varambally S, Kurachi K, Pienta KJ, Rubin MA, Chinnaiyan AM. Delineation of prognostic biomarkers in prostate cancer. *Nature* 2001;412:822-6.
145. Luo J, Duggan DJ, Chen Y, Sauvageot J, Ewing CM, Bittner ML, Trent JM, Isaacs WB. Human prostate cancer and benign prostatic hyperplasia: molecular dissection by gene expression profiling. *Cancer Res* 2001;61:4683-8.
146. Magee JA, Araki T, Patil S, Ehrig T, True L, Humphrey PA, Catalona WJ, Watson MA, Milbrandt J. Expression profiling reveals hepsin overexpression in prostate cancer. *Cancer Res* 2001;61:5692-6.
147. Stamey TA, Warrington JA, Caldwell MC, Chen Z, Fan Z, Mahadevappa M, McNeal JE, Nolley R, Zhang Z. Molecular genetic profiling of Gleason grade 4/5 prostate cancers compared to benign prostatic hyperplasia. *J Urol* 2001;166:2171-7.
148. **Stephan C**, Yousef GM, Scorilas A, Jung K, Jung M, Kristiansen G, Hauptmann S, Kishi T, Nakamura T, Loening SA, Diamandis EP. Hepsin is highly over expressed in and a new candidate for a prognostic indicator in prostate cancer. *J Urol* 2004;171:187-91.
149. Torres-Rosado A, O'Shea KS, Tsuji A, Chou SH, Kurachi K. Hepsin, a putative cell-surface serine protease, is required for mammalian cell growth. *Proc Natl Acad Sci U S A* 1993;90:7181-5.
150. Kazama Y, Hamamoto T, Foster DC, Kisiel W. Hepsin, a putative membrane-associated serine protease, activates human factor VII and initiates a pathway of blood coagulation on the cell surface leading to thrombin formation. *J Biol Chem* 1995;270:66-72.
151. Nakamura T, **Stephan C**, Scorilas A, Yousef GM, Jung K, Diamandis EP. Quantitative analysis of hippostasin/KLK11 gene expression in cancerous and noncancerous prostatic tissues. *Urology* 2003;61:1042-6.
152. Nakamura T, Scorilas A, **Stephan C**, Yousef GM, Kristiansen G, Jung K, Diamandis EP. Quantitative analysis of macrophage inhibitory cytokine-1 (MIC-1) gene expression in human prostatic tissues. *Br J Cancer* 2003;88:1101-4.
153. Kristiansen G, Pilarsky C, Wissmann C, **Stephan C**, Weissbach L, Loy V, Loening SA, Dietel M, Rosenthal A. ALCAM/CD166 is upregulated in low-grade prostate cancer and progressively lost in high-grade lesions. *Prostate* 2003;54:34-43.
154. Kristiansen G, Pilarsky C, Pervan J, Sturzebecher B, **Stephan C**, Jung K, Loening S, Rosenthal A, Dietel M. CD24 expression is a significant predictor of PSA relapse and poor prognosis in low grade or organ confined prostate cancer. *Prostate* 2004;58:183-92.
155. Kristiansen G, Pilarsky C, Wissmann C, Kaiser S, Bruemendorf T, Roepcke S, Dahl E, Hinzmann B, Specht T, Pervan J, **Stephan C**, Loening S, Dietel M, Rosenthal A. Expression profiling of microdissected matched prostate cancer samples reveals CD166/MEMD and CD24 as new prognostic markers for patient survival. *J Pathol* 2005;205:359-76.
156. Weichert W, Schmidt M, Gekeler V, Denkert C, **Stephan C**, Jung K, Loening S, Dietel M, Kristiansen G. Polo-like kinase 1 is overexpressed in prostate cancer and linked to higher tumor grades. *Prostate* 2004;60:240-5.
157. Xu C, Jung M, Burkhardt M, **Stephan C**, Schnorr D, Loening S, Jung K, Dietel M, Kristiansen G. Increased CD59 protein expression predicts a PSA relapse in patients after radical prostatectomy. *Prostate* 2005;62:224-32.
158. Jung M, Xu C, Spethmann J, Johannsen M, Deger S, **Stephan C**, Loening SA, Jung K. Re: Hessels D, Klein Gunnewiek JMT, van Oort I, Karthaus HFM, van Leenders GJL, van Balken B, Kiemeny LA, Witjes JA, Schalken JA. DD3(PCA3)-based molecular urine analysis for the diagnosis of prostate cancer. *Eur Urol* 2003;44:8-16. *Eur Urol* 2004;46:271-2.

7.2 Eigene Publikationen als Erstautor und Koautor (Nr. 1 bis 13 entsprechen E1-E13)

1. **Stephan C**, Lein M, Jung K, Schnorr D, Loening SA. The influence of prostate volume on the ratio of free to total prostate specific antigen in serum of patients with prostate cancer and benign prostatic hyperplasia. *Cancer* 1997;79:104-9.
2. **Stephan C**, Stroebe G, Heinau M, Lenz A, Roemer A, Lein M, Schnorr D, Loening SA, Jung K. The ratio of prostate-specific antigen (PSA) to prostate volume (PSA density) as a parameter to improve the detection of prostate carcinoma in PSA values in the range of < 4 ng/mL. *Cancer* 2005;104:993-1003.
3. **Stephan C**, Jung K, Brux B, Lein M, Sinha P, Schnorr D, Loening SA. ACT-PSA and complexed PSA elimination kinetics in serum after radical retropubic prostatectomy: a proof of new complex forming of PSA after release into circulation. *Urology* 2000;55:560-3.
4. **Stephan C**, Jung K, Lein M, Sinha P, Schnorr D, Loening SA. Molecular forms of prostate-specific antigen and human kallikrein 2 as promising tools for early diagnosis of prostate cancer. *Cancer Epidemiol Biomark Prevent* 2000;9:1133-47.
5. **Stephan C**, Wesseling S, Schink T, Jung K. Comparison of eight computer programs for receiver-operating characteristic (ROC) analysis. *Clin Chem* 2003;49:433-9.
6. **Stephan C**, Jung K, Cammann H, Vogel B, Brux B, Kristiansen G, Rudolph B, Hauptmann S, Lein M, Schnorr D, Sinha P, Loening SA. An artificial neural network considerably improves the diagnostic power of percent free prostate-specific antigen in prostate cancer diagnosis - results of a 5-year investigation. *Int J Cancer* 2002;99:466-73.
7. **Stephan C**, Cammann H, Semjonow A, Diamandis EP, Wymenga LFA, Lein M, Sinha P, Loening SA, Jung K. Multicenter evaluation of an artificial neural network to increase prostate cancer detection rate and reduce unnecessary biopsies. *Clin Chem* 2002;48:1279-87.
8. **Stephan C**, Klaas M, Müller C, Schnorr D, Loening SA, Jung K. Interchangeability of measurements of total and free prostate-specific antigen in serum with 5 frequently used assay combinations: an update. *Clin Chem* 2006;in press.
9. **Stephan C**, Xu C, Brown DA, Breit SN, Michael A, Nakamura T, Diamandis EP, Cammann H, Jung K. Three new serum markers for prostate cancer detection within a percent free PSA based artificial neural network. *Prostate* 2006;in press.
10. **Stephan C**, Jung K, Diamandis EP, Rittenhouse HG, Lein M, Loening SA. Prostate specific antigen, its molecular forms and other kallikrein markers for detection of prostate cancer. *Urology* 2002;59:2-8.
11. **Stephan C**, Jung K, Soosaipillai A, Yousef GM, Cammann H, Meyer H, Xu C, Diamandis EP. Clinical utility of human glandular kallikrein 2 within a neural network for prostate cancer detection. *BJU Int* 2005;96:521-7.
12. **Stephan C**, Yousef GM, Scorilas A, Jung K, Jung M, Kristiansen G, Hauptmann S, Bharaj BS, Nakamura T, Loening SA, Diamandis EP. Quantitative analysis of kallikrein 15 (KLK15) gene expression in prostate tissue. *J Urol* 2003;169:361-4.
13. **Stephan C**, Yousef GM, Scorilas A, Jung K, Jung M, Kristiansen G, Hauptmann S, Kishi T, Nakamura T, Loening SA, Diamandis EP. Hepsin is highly over expressed in and a new candidate for a prognostic indicator in prostate cancer. *J Urol* 2004;171:187-91.
14. **Stephan C**, Jung K, Lein M, Henke W, Schnorr D, Brux B, Loening S. Freies prostataspezifisches Antigen im Serum: eine Meßgröße zur Diskrimination zwischen Patienten mit Prostatakarzinom und benigner Prostatahyperplasie. *J Lab Med* 1996;20:7-12.
15. **Stephan C**, Jung K, Lein M, Schnorr D, Loening SA. The ratio of free to total prostate specific antigen in serum is correlated to the prostate volume. *Int J Cancer* 1996;67:461-2.
16. **Stephan C**, Jung K, Brux B, Sinha P, Lein M, Schnorr D, Loening SA. Elimination of serum complexed prostate-specific antigen after radical retropubic prostatectomy. *Clin Chem Lab Med* 2000;38:309-11.
17. **Stephan C**, Vogel B, Cammann H, Lein M, Klevecka V, Sinha P, Kristiansen G, Schnorr D, Jung K, Loening SA. Nutzung von artifiziellen neuronalen Netzwerken zur Risikoabschätzung eines Prostatakarzinoms: Biopsieindikationen im PSA-Bereich 2-20 µg/l. *Urologe A* 2003;42:1221-9.
18. **Stephan C**, Lein M, Jung K, Schnorr D, Loening SA. Can prostate specific antigen derivatives reduce the frequency of unnecessary prostate biopsies?[Letter]. *J Urol* 1997;157:1371.
19. **Stephan C**, Jung K, Lein M, Schnorr D, Loening SA. Re: Complexed prostate specific antigen provides significant enhancement of specificity compared with total prostate specific antigen for detecting prostate cancer. *J Urol* 2000;164:1671-2.
20. **Stephan C**, Araujo FF, Herzenberg JE. Accurate determination of cast weight for neonates with clubfoot. *J Pediatr Orthop* 2000;20:230-3.
21. **Stephan C**, Jung K, Schnorr D, Lein M, Sinha P, Loening SA. Re: A prospective study to evaluate the role of complexed prostate specific antigen and free/total prostate specific antigen ratio for the diagnosis of prostate cancer. I.D.C. Mitchell, B.L. Croal, A. Dickie, N.P. Cohen and I. Ross. *J Urol*, 165: 1549-1553, 2001. *J Urol* 2002;167:259-60.
22. **Stephan C**, Jung K, Sinha P. Tumor markers for prostatic cancer - which way in this millenium? *Res Adv in Cancer* 2002;2:147-57.

23. **Stephan C**, Jung K. Indirect free PSA and other molecular forms of PSA: Are there new tools for prostate cancer detection? *LabMedica Int* 2004;21:15-9.
24. **Stephan C**, Jung K, Cammann H. Predictive modeling for the presence of prostate carcinoma using clinical, laboratory, and ultrasound parameters in patients with prostate-specific antigen levels ≤ 10 ng/ml. *Cancer* 2004;100:1989-90.
25. **Stephan C**, Lein M, Schnorr D, Loening SA, Jung K. Repeating the measurement of prostate-specific antigen in symptomatic men can avoid unnecessary prostatic biopsy. *BJU Int* 2004;93:1360-1.
26. **Stephan C**, Cammann H, Jung K. Risikobewertung per Mausclick. *Dtsch Arztebl* 2004;101:B672-B673.
27. **Stephan C**, Jung K, Cammann H. Improved selection for prostate biopsy. *Brit Med J* 2004;<http://bmj.com/cgi/eletters/327/7425/1227#45601>.
28. **Stephan C**, Cammann H, Jung K. Prostatakrebs: Risikobewertung per Mausclick. *PraxisComputer* 2004;20:10-1.
29. **Stephan C**, Lein M, Jung K, Loening SA. Titelthema PSA-Screening. *Leserbrief. Berliner Ärzte* 2005;42:13.
30. **Stephan C**, Kristiansen G, Jung K. Practice Point: Is NF-B predictive of biochemical recurrence in positive-margin prostate cancer? *Nature Clin Pract Urol* 2005;2:134-5.
31. **Stephan C**, Cammann H, Jung K. Viewpoint: Artificial neural networks: has the time come for their use in prostate cancer patients? *Nature Clin Pract Urol* 2005;2:262-3.
32. **Stephan C**, Yousef GM, Jung K, Diamandis EP. Prostate specific antigen and other kallikreins in prostate cancer. In: Paschalides P, ed. *Prostate Cancer: Understanding the Pathophysiology and Redesigning a Therapeutic Approach*. 2005:in press.
33. **Stephan C**, Cammann H, Jung K, Loening SA. Multivariate models for decreasing unnecessary biopsies for prostate cancer. In: Kirby R, Partin AW, Feneley M, Kellogg Parsons J, eds. *Prostate Cancer: Principles and Practice*. 2005.
34. **Stephan C**, Schnorr D, Loening SA, Jung K. Re: Roddam AW, Duffy MJ, Hamdy FC, et al. Use of prostate-specific antigen (PSA) isoforms for the detection of prostate cancer in men with a PSA level of 2-10 ng/ml: systematic review and meta-analysis. *Eur Urol* 2005;48:386-99. *Eur Urol* 2005;48:1059-60.
35. Jung K, **Stephan C**, Lein M, Henke W, Schnorr D, Brux B, Schürenkämper P, Loening SA. Analytical performance and clinical validity of two free prostate-specific antigen assays compared. *Clin Chem* 1996;42:1026-33.
36. Lein M, Jung K, **Stephan C**, Lenk S, Schnorr D, Loening SA. PSA-Quotient ist spezifischer als Absolutwerte. *TW Urologie Nephrologie* 1997;9:235-7.
37. Lein M, Brux B, Jung K, Henke W, Koenig F, **Stephan C**, Schnorr D, Loening SA. Elimination of serum free and total prostate-specific antigen after radical retropubic prostatectomy. *Eur J Clin Chem Clin Biochem* 1997;35:591-5.
38. Lein M, **Stephan C**, Jung K, Koenig F, Schnorr D, Loening SA. Das Verhältnis freies PSA/Gesamt-PSA - eine Kenngröße zur Differenzierung zwischen Patienten mit Prostatakarzinom und benigner Hyperplasie: Welcher Diskriminationspunkt sollte gewählt werden? *Akt Urol* 1997;28:323-8.
39. Lein M, **Stephan C**, Jung K, Schnorr D, Loening S. Relation of free PSA/total PSA in serum for differentiating between patients with prostatic cancer and benign hyperplasia of the prostate - which cutoff should be used? *Cancer Invest* 1998;16:45-9.
40. Lein M, Jung K, Laube C, Hübner T, Winkelmann B, **Stephan C**, Hauptmann S, Rudolph B, Schnorr D, Loening SA. Matrix metalloproteinases and their inhibitors in plasma and tumor tissue of patients with renal cell carcinoma. *Int J Cancer* 2000;85:801-4.
41. Lein M, **Stephan C**, Jung K, Schnorr D, Loening SA. Molekulare Formen des prostataspezifischen Antigens und des humanen Kallikreins₂ als mögliche Indikatoren in der Prostatakarzinomdiagnostik. *Urologe A* 2000;39:313-23.
42. Magklara A, Scorilas A, **Stephan C**, Kristiansen GO, Hauptmann S, Jung K, Diamandis EP. Decreased concentrations of prostate-specific antigen and human glandular kallikrein 2 in malignant versus non-malignant prostatic tissue. *Urology* 2000;56:527-32.
43. Lein M, Jung K, Elgeti U, Petras T, **Stephan C**, Brux B, Sinha P, Winkelmann B, Schnorr D, Loening S. Comparison of the clinical validity of free prostate-specific antigen, alpha-1-antichymotrypsin-bound prostate-specific antigen and complexed prostate-specific antigen in prostate cancer diagnosis. *Eur Urol* 2001;39:57-64.
44. Jung K, **Stephan C**, Lein M, Brux B, Sinha P, Schnorr D, Loening SA. Receiver-operating characteristic as a tool for evaluating the diagnostic performance of prostate-specific antigen and its molecular forms-What has to be considered? *Prostate* 2001;46:307-10.
45. Lein M, Jung K, Hammerer P, Graefen M, Semjonow A, Stieber P, Ossendorf M, Luboldt H-J, Brux B, **Stephan C**, Schnorr D, Loening SA. A multicenter clinical trial on the use of alpha₁-antichymotrypsin-prostate specific antigen in prostate cancer diagnosis. *Prostate* 2001;47:77-84.
46. Scorilas A, Yousef GM, Jung K, Rajpert-De Meyts E, **Stephan C**, Diamandis EP. Identification and characterization of a novel human testis-specific kinase substrate gene which is downregulated in testicular tumors. *Biochem Biophys Res Commun* 2001;285:400-8.
47. Jung K, **Stephan C**, Elgeti U, Lein M, Brux B, Kristiansen G, Rudolph B, Hauptmann S, Schnorr D, Loening SA. Molecular forms of prostate-specific antigen in serum with concentrations of total prostate-

- specific antigen <4 µg/l - are they useful tools for early detection and screening of prostate cancer? *Int J Cancer* 2001;93:759-65.
48. Bharaj BS, Luo L-Y, Jung K, **Stephan C**, Diamandis EP. Identification of single nucleotide polymorphisms in the human kallikrein 10 (KLK10) gene and their association with prostate, breast, testicular, and ovarian cancers. *Prostate* 2002;51:35-41.
 49. Lein M, Jung K, Ortel B, **Stephan C**, Rothaug W, Johannsen M, Deger S, Schnorr D, Loening S, Krell H-W. The new synthetic matrix metalloproteinase inhibitor (Roche 28-2653) reduces tumor growth and prolongs survival in a prostate cancer standard rat model. *Oncogene* 2002;21:2089-96.
 50. Obiezu CV, Soosaipillai A, Jung K, **Stephan C**, Scorilas A, Howarth DHC, Diamandis EP. Detection of human kallikrein 4 (HK4) in normal and cancerous prostatic tissues by immunofluorometry and immunohistochemistry. *Clin Chem* 2002;48:1232-40.
 51. Yousef GM, Obiezu CV, Jung K, **Stephan C**, Scorilas A, Diamandis EP. Differential expression of kallikrein gene 5 in cancerous and normal testicular tissues. *Urology* 2002;60:714-8.
 52. Yousef GM, **Stephan C**, Scorilas A, Ellatif MA, Jung K, Kristiansen G, Jung M, Polymeris M-E, Diamandis EP. Differential expression of the human kallikrein gene 14 (KLK14) in normal and prostate cancer tissues. *Prostate* 2003;56:287-92.
 53. Nakamura T, Scorilas A, **Stephan C**, Yousef GM, Kristiansen G, Jung K, Diamandis EP. Quantitative analysis of macrophage inhibitory cytokine-1 (MIC-1) gene expression in human prostatic tissues. *Br J Cancer* 2003;88:1101-4.
 54. Nakamura T, Scorilas A, **Stephan C**, Jung K, Soosaipillai A, Diamandis EP. The usefulness of serum human kallikrein 11 for discriminating between prostate cancer and benign prostatic hyperplasia. *Cancer Res* 2003;63:6543-6.
 55. Kristiansen G, Pilarsky C, Wissmann C, **Stephan C**, Weissbach L, Loy V, Loening SA, Dietel M, Rosenthal A. ALCAM/CD166 is upregulated in low-grade prostate cancer and progressively lost in high-grade lesions. *Prostate* 2003;54:34-43.
 56. Beyersdorff D, Darsow U, **Stephan C**, Schnorr D, Loening S, Taupitz M. MRI of prostate cancer using three different coil systems: image quality, tumor detection, and staging. *Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr* 2003;175:799-805.
 57. Nakamura T, **Stephan C**, Scorilas A, Yousef GM, Jung K, Diamandis EP. Quantitative analysis of hippostasin/KLK11 gene expression in cancerous and noncancerous prostatic tissues. *Urology* 2003;61:1042-6.
 58. Lein M, Kwiatkowski M, Semjonow A, Luboldt HJ, Hammerer P, **Stephan C**, Klevecka V, Taymoorian K, Schnorr D, Recker F, Loening SA, Jung K. A multicenter clinical trial on the use of complexed prostate specific antigen in low prostate specific antigen concentrations. *J Urol* 2003;170:1175-9.
 59. Lichtinghagen R, Musholt PB, **Stephan C**, Lein M, Kristiansen G, Hauptmann S, Rudolph B, Schnorr D, Loening SA, Jung K. mRNA expression profile of matrix metalloproteinases and their tissue inhibitors in malignant and non-malignant prostatic tissue. *Anticancer Res* 2003;23:2617-24.
 60. Wesseling S, **Stephan C**, Semjonow A, Lein M, Brux B, Sinha P, Loening SA, Jung K. Determination of non-alpha-1-antichymotrypsin-complexed prostate-specific antigen as an indirect measurement of free prostate-specific antigen: analytical performance and diagnostic accuracy. *Clin Chem* 2003;49:887-94.
 61. Jung K, **Stephan C**, Semjonow A, Lein M, Schnorr D, Loening SA. Serum osteoprotegerin and receptor activator of nuclear factor-kB ligand as indicators of disturbed osteoclastogenesis in patients with prostate cancer. *J Urol* 2003;170:2302-5.
 62. Remzi M, Anagnostou T, Ravery V, Zlotta A, **Stephan C**, Marberger M, Djavan B. An artificial neural network to predict the outcome of repeat prostate biopsies. *Urology* 2003;62:456-60.
 63. Kristiansen G, Pilarsky C, Pervan J, Sturzebecher B, **Stephan C**, Jung K, Loening S, Rosenthal A, Dietel M. CD24 expression is a significant predictor of PSA relapse and poor prognosis in low grade or organ confined prostate cancer. *Prostate* 2004;58:183-92.
 64. Jung K, **Stephan C**, Lewandowski M, Klotzek S, Jung M, Kristiansen G, Lein M, Loening SA, Schnorr D. Increased cell-free DNA in plasma of patients with metastatic spread in prostate cancer. *Cancer Lett* 2004;205:173-80.
 65. Michael A, **Stephan C**, Schnorr D, Loening SA, Jung K. Serum macrophage migration inhibitory factor is not elevated in patients with prostate cancer. *Cancer Epidemiol Biomarkers Prev* 2004;13:328-9.
 66. Weichert W, Schmidt M, Gekeler V, Denkert C, **Stephan C**, Jung K, Loening S, Dietel M, Kristiansen G. Polo-like kinase 1 is overexpressed in prostate cancer and linked to higher tumor grades. *Prostate* 2004;60:240-5.
 67. Brown DA, **Stephan C**, Ward RL, Law M, Hunter M, Bauskin AR, Amin J, Jung K, Diamandis EP, Hampton GM, Russell PJ, Giles GG, Breit SN. Serum macrophage inhibitory cytokine (MIC-1) levels for the diagnosis and tumor grading of prostate cancer. *Clin Cancer Res* 2005;accepted.
 68. Jung K, Lein M, **Stephan C**, Von Hosslin K, Semjonow A, Sinha P, Loening SA, Schnorr D. Comparison of 10 serum bone turnover markers in prostate carcinoma patients with bone metastatic spread: diagnostic and prognostic implications. *Int J Cancer* 2004;111:783-91.

69. Michael A, **Stephan C**, Kristiansen G, Burckhardt M, Loening SA, Schnorr D, Jung K. Diagnostic validity of macrophage migration inhibitory factor in serum of patients with prostate cancer: a re-evaluation. *Prostate* 2005;62:34-9.
70. Kristiansen G, Pilarsky C, Wissmann C, Kaiser S, Bruemmendorf T, Roepcke S, Dahl E, Hinzmann B, Specht T, Pervan J, **Stephan C**, Loening S, Dietel M, Rosenthal A. Expression profiling of microdissected matched prostate cancer samples reveals CD166/MEMD and CD24 as new prognostic markers for patient survival. *J Pathol* 2005;205:359-76.
71. Jung M, Xu C, Spethmann J, Johannsen M, Deger S, **Stephan C**, Loening SA, Jung K. Re: Hessels D, Klein Gunnewiek JMT, van Oort I, Karthaus HFM, van Leenders GJL, van Balken B, Kiemeneys LA, Witjes JA, Schalken JA. DD3(PCA3)-based molecular urine analysis for the diagnosis of prostate cancer. *Eur Urol* 2003;44:8-16. *Eur Urol* 2004;46:271-2.
72. Kurlender L, Yousef GM, Memari N, Robb JD, Michael IP, Borgono C, Katsaros D, **Stephan C**, Jung K, Diamandis EP. Differential expression of a human kallikrein 5 (KLK5) splice variant in ovarian and prostate cancer. *Tumour Biol* 2004;25:149-56.
73. Yousef GM, Borgono CA, Michael IP, Davidian C, **Stephan C**, Jung K, Diamandis EP. Molecular cloning of a new gene which is differentially expressed in breast and prostate cancers. *Tumour Biol* 2004;25:122-33.
74. Xu C, Jung M, Burkhardt M, **Stephan C**, Schnorr D, Loening S, Jung K, Dietel M, Kristiansen G. Increased CD59 protein expression predicts a PSA relapse in patients after radical prostatectomy. *Prostate* 2005;62:224-32.
75. Yousef GM, White NM, Kurlender L, Michael I, Memari N, Robb JD, Katsaros D, **Stephan C**, Jung K, Diamandis EP. The kallikrein gene 5 splice variant 2 is a new biomarker for breast and ovarian cancer. *Tumour Biol* 2004;25:221-7.
76. Jung K, Reiche J, Boehme A, **Stephan C**, Loening SA, Schnorr D, Hoesel W, Sinha P. Analysis of subforms of free prostate-specific antigen in serum by two-dimensional gel electrophoresis: potential to improve diagnosis of prostate cancer. *Clin Chem* 2004;50:2292-301.
77. Michael IP, Kurlender L, Memari N, Yousef GM, Du D, Grass L, **Stephan C**, Jung K, Diamandis EP. Intron retention: a common splicing event within the human kallikrein gene family. *Clin Chem* 2005;51:506-15.
78. Roemer A, Schwettmann L, Jung M, **Stephan C**, Roigas J, Kristiansen G, Loening SA, Lichtinghagen R, Jung K. The membrane proteases adam10 and hepsin are differentially expressed in renal cell carcinoma. Are they potential tumor markers? *J Urol* 2004;172:2162-6.
79. Keller T, Butz H, Lein M, Kwiatkowski M, Semjonow A, Luboldt HJ, Hammerer P, **Stephan C**, Jung K. Discordance analysis characteristics as a new method to compare the diagnostic accuracy of tests: example of complexed versus total prostate-specific antigen. *Clin Chem* 2005;51:532-9.
80. Abramjuk C, Jung K, Krell HW, Juchem R, Peters R, Taymoorian K, Staack A, **Stephan C**, Schnorr D, Loening SA, Lein M. Matrix metalloproteinase inhibitor Ro 28-2653 in combination with estramustine: tumor-reducing effects on hormone-sensitive prostate cancer in rats. *Anticancer Drugs* 2005;16:855-61.
81. Lein M, Semjonow A, Graefen M, Kwiatkowski M, Abramjuk C, **Stephan C**, Haese A, Chun F, Schnorr D, Loening SA, Jung K. A multicenter clinical trial on the use of (-5, -7) pro prostate specific antigen. *J Urol* 2005;174:2150-3.
82. Ohl F, Jung M, Xu C, **Stephan C**, Rabien A, Burkhardt M, Nitsche A, Kristiansen G, Loening SA, Radonic A, Jung K. Gene expression studies in prostate cancer tissue: which reference gene should be selected for normalization? *J Mol Med* 2005.
83. Jung K, Lein M, Butz H, **Stephan C**, Loening SA, Keller T. New Insights into the Diagnostic Accuracy of Complexed and Total Prostate Specific Antigen Using Discordance Analysis Characteristics. *J Urol* 2006;in press.
84. **Stephan C**, Jung K, Nakamura T, Yousef GM, Kristiansen G, Diamandis EP. Serum human glandular kallikrein 2 (hK2) for distinguishing stage and grade of prostate cancer. *Int J Urol* 2005;accepted.
85. Costa A, Gennari R, Andreoli C, Betka J, **Stephan C**, Hugosson J, Llovet JM, Melia J, Nakhosteen JA, Quaranta M, Rosselli del Turco M, Schittulli F, Sideri M, Zurrada S, Veronesi U. Individual Risk Assessment and Early Detection of Cancer. *Eur J Cancer* 2005;submitted.
86. **Stephan C**, Xu C, Cammann H, Graefen M, Haese A, Huland H, Semjonow A, Diamandis EP, Remzi M, Djavan B, Wildhagen MF, Blijenberg BG, Finne P, Stenman UH, Meyer H, Jung K. Assay-specific artificial neural networks for 5 different PSA assays and populations with PSA 2-10 ng/mL in 4480 men. *Cancer* 2005;submitted.
87. Sturm I, **Stephan C**, Gillissen B, Siebert R, Janz M, Radetzki S, Jung K, Loening S, Dörken B, Daniel PT. Loss of the tissue-specific proapoptotic BH3-only protein Nbk/Bik is a unifying feature of renal cell carcinoma. *Cell Death Differ* 2005;in press.
88. **Stephan C**, Meyer H, Kwiatkowski M, Recker F, Cammann H, Loening SA, Jung K, Lein M. A (-5, -7) Pro PSA based artificial neuronal network to detect prostate cancer. *Eur Urol* 2005;submitted.